Results 121 to 130 of about 5,436 (148)

Novel insights into diagnosis and management of hyperreactivity: a narrative review. [PDF]

J Thorac Dis
Liu X, Cai Q, Lin L, Deng H, Zeng R, Shi J, Huang L, Liu H, Li C, Li J, Cheng B, Liu H, Thiery JP, Liang W, He J.   +14 more
europepmc   +1 more source

Roles of vasopressin in renal blood flow and vascular resistance in male mice after treadmill running: A mechanism for ALPE. [PDF]

Physiol Rep
Nomura K, Tanida M, Akai R, Yabe T, Fujii A, Nomura K, Okada K, Okino K, Hayashi N, Fujimoto K, Kurata Y, Iwawaki T, Furuichi K.   +12 more
europepmc   +1 more source

The Renin-Angiotensin-Aldosterone System (RAAS): Beyond Cardiovascular Regulation. [PDF]

Vet Sci
Valentini A, Heilmann RM, Kühne A, Biagini L, De Bellis D, Rossi G.   +5 more
europepmc   +1 more source

Cryo-EM structures of GnRHR: Foundations for next-generation therapeutics. [PDF]

Proc Natl Acad Sci U S A
Shen S, He X, Liu H, Hu W, Xu HE, Duan J.   +5 more
europepmc   +1 more source

Psychogenic Polydipsia Presenting as Recurrent Hyponatremic Seizures in a Patient With Schizoaffective Disorder. [PDF]

Cureus
Gupta RR, S G G, Chaukimath S, Ramdurg S, Kalasagond MB.   +4 more
europepmc   +1 more source

Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19. [PDF]

Int J Med Sci
Wu B, Li R, Liu Q, Jin S, Wei H, Xu M, Zhang Y, Liu Y.   +7 more
europepmc   +1 more source

Are There Connections between the Neuroendocrine and Dopamine Systems in Bipolar Disorder?

Neuroendocrinology
Trouillas J, Claustrat B, Henry E, Lemius J, Alafuzoff I, Nataf S.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Effects of an oral vasopressin receptor antagonist (OPC‐31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone

Australian Veterinary Journal, 2000
ObjectiveThe syndrome of inappropriate secretion of antidiuretic hormone is a rare disorder in dogs characterised by hypo‐osmolality and persistent arginine vasopressin production in the absence of hypovolaemia and/or hypotension. The study describes the efficacy and safety of the nonpeptide selective arginine vasopressin V2receptor antagonist OPC ...
Fleeman, LM, Irwin, PJ, Phillips, PA, West, J   +3 more
openaire   +3 more sources

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

European Journal of Clinical Pharmacology, 2011
Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases.
Gassanov, Natig, Semmo, Nasser, Semmo, Mariam, Nia, Amir M., Fuhr, Uwe, Er, Fikret   +5 more
openaire   +3 more sources